Altimmune Inc. Common Stock

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Semicondct Bull 3X ETF

Direxion Daily FTSE China Bull 3X ETF

Mast Therapeutics, Inc.

GraniteShares 1.5x Long META Daily ETF

Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

GraniteShares 2x Long AMZN Daily ETF

Direxion Daily Financial Bull 3X ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

VS TR 2x Long VIX Futures ETF

T-REX 2X Inverse Tesla Daily Target ETF

Direxion Daily Small Cap Bear 3X ETF

Direxion Financial Bear 3X Shar

ProShares Ultra VIX Short-Term Futures

GraniteShares 1.5x Short NVDA Daily ETF

Polyrizon Ltd. Ordinary Shares

Classover Holdings Inc. Class B Common Stock

Freight Technologies Inc. Ordinary Shares

IBO (Listing Market - NYSE Amex Network B F)

Cooper-Standard Holdings Inc. Common Stock

Adaptive Biotechnologies Corporation Common Stock

Wolfspeed Inc. Common Stock

AgEagle Aerial Systems Inc. Common Stock

Duolingo Inc. Class A Common Stock

Trupanion Inc. Common Stock

Zoomcar Holdings Inc. Common Stock

Pro-Dex Inc. Common Stock

Block Inc. Class A Common Stock

Nvni Group Limited Ordinary Shares

fuboTV Inc. Common Stock

Hecla Mining Company Common Stock

Cytokinetics Incorporated Common Stock

Huntsman Corporation Common Stock

Atlassian Corporation Class A Common Stock

Autonomix Medical Inc. Common Stock

Click here to get full coverage on Biohaven Announces Investment up to $600 Million by Oberland Capital - PR Newswire

Biohaven Announces Investment up to $600 Million by Oberland Capital  PR Newswire

Biohaven Announces Investment up to $600 Million by Oberland Capital - PR Newswire

Click here to get full coverage on Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Yahoo Finance

Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts?  Yahoo Finance

Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Yahoo Finance

Click here to get full coverage on $BHVN stock is up 7% today. Here's what we see in our data. - Nasdaq

$BHVN stock is up 7% today. Here's what we see in our data.  Nasdaq

$BHVN stock is up 7% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Where are the Opportunities in (BHVN) - news.stocktradersdaily.com

Where are the Opportunities in (BHVN)  news.stocktradersdaily.com

Where are the Opportunities in (BHVN) - news.stocktradersdaily.com

Click here to get full coverage on Biohaven Lands Massive $600M Backing to Advance First-Ever Treatment for Rare Genetic Disease - Stock Titan

Biohaven Lands Massive $600M Backing to Advance First-Ever Treatment for Rare Genetic Disease  Stock Titan

Biohaven Lands Massive $600M Backing to Advance First-Ever Treatment for Rare Genetic Disease - Stock Titan

Click here to get full coverage on BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm - Business Wire

BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm  Business Wire

BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm - Business Wire

Click here to get full coverage on Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results  PR Newswire

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Click here to get full coverage on Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21 - Yahoo Finance

Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21  Yahoo Finance

Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21 - Yahoo Finance

Click here to get full coverage on Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting - PR Newswire

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting  PR Newswire

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting - PR Newswire

Click here to get full coverage on Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025 - Yahoo Finance

Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025  Yahoo Finance

Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025 - Yahoo Finance

Click here to get full coverage on Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - PR Newswire

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments  PR Newswire

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - PR Newswire

Click here to get full coverage on Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity - PR Newswire

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity  PR Newswire

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity - PR Newswire

Click here to get full coverage on Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - PR Newswire

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300  PR Newswire

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - PR Newswire

Click here to get full coverage on Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - PR Newswire

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia  PR Newswire

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - PR Newswire

Click here to get full coverage on Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PR Newswire

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates  PR Newswire

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PR Newswire

Click here to get full coverage on Biohaven Announces Proposed Public Offering of Common Shares - PR Newswire

Biohaven Announces Proposed Public Offering of Common Shares  PR Newswire

Biohaven Announces Proposed Public Offering of Common Shares - PR Newswire

Click here to get full coverage on Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - PR Newswire

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares  PR Newswire

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - PR Newswire

Click here to get full coverage on Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio - PR Newswire

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio  PR Newswire

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio - PR Newswire

Click here to get full coverage on Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments - PR Newswire

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments  PR Newswire

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments - PR Newswire

Click here to get full coverage on Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting - PR Newswire

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting  PR Newswire

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting - PR Newswire

Click here to get full coverage on Biohaven (BHVN) Secures Up to $600M Investment from Oberland Cap - GuruFocus

Biohaven (BHVN) Secures Up to $600M Investment from Oberland Cap  GuruFocus

Biohaven (BHVN) Secures Up to $600M Investment from Oberland Cap - GuruFocus

Click here to get full coverage on Biohaven's Next-Gen Neuroscience Pipeline: 13 Groundbreaking Studies Target Parkinson's and Migraine - Stock Titan

Biohaven's Next-Gen Neuroscience Pipeline: 13 Groundbreaking Studies Target Parkinson's and Migraine  Stock Titan

Biohaven's Next-Gen Neuroscience Pipeline: 13 Groundbreaking Studies Target Parkinson's and Migraine - Stock Titan

Click here to get full coverage on Why Biohaven (BHVN) Stock Is Rallying Today - Yahoo Finance

Why Biohaven (BHVN) Stock Is Rallying Today  Yahoo Finance

Why Biohaven (BHVN) Stock Is Rallying Today - Yahoo Finance

Click here to get full coverage on First Week of BHVN October 17th Options Trading - Nasdaq

First Week of BHVN October 17th Options Trading  Nasdaq

First Week of BHVN October 17th Options Trading - Nasdaq

Click here to get full coverage on Biohaven (BHVN) Price Target Cut by Baird Amid Regulatory Develo - GuruFocus

Biohaven (BHVN) Price Target Cut by Baird Amid Regulatory Develo  GuruFocus

Biohaven (BHVN) Price Target Cut by Baird Amid Regulatory Develo - GuruFocus

Click here to get full coverage on Notable Thursday Option Activity: CELH, AMD, BHVN - Nasdaq

Notable Thursday Option Activity: CELH, AMD, BHVN  Nasdaq

Notable Thursday Option Activity: CELH, AMD, BHVN - Nasdaq

Click here to get full coverage on New Analyst Forecast: $BHVN Given $60.0 Price Target - Nasdaq

New Analyst Forecast: $BHVN Given $60.0 Price Target  Nasdaq

New Analyst Forecast: $BHVN Given $60.0 Price Target - Nasdaq

Click here to get full coverage on Independent Director of Biohaven John Childs Buys More Stock - simplywall.st

Independent Director of Biohaven John Childs Buys More Stock  simplywall.st

Independent Director of Biohaven John Childs Buys More Stock - simplywall.st

Click here to get full coverage on Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland - Benzinga

Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland  Benzinga

Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland - Benzinga

Click here to get full coverage on Biohaven's Exciting Year Of Catalysts (NYSE:BHVN) - Seeking Alpha

Biohaven's Exciting Year Of Catalysts (NYSE:BHVN)  Seeking Alpha

Biohaven's Exciting Year Of Catalysts (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN) - Seeking Alpha

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN)  Seeking Alpha

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on Biohaven (BHVN) Stock Drops After Withdrawal of EU Drug Applicat - GuruFocus

Biohaven (BHVN) Stock Drops After Withdrawal of EU Drug Applicat  GuruFocus

Biohaven (BHVN) Stock Drops After Withdrawal of EU Drug Applicat - GuruFocus

Click here to get full coverage on Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - StreetInsider

Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300  StreetInsider

Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - StreetInsider

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN - PR Newswire

Click here to get full coverage on Biohaven (BHVN) Faces Market Setback After EMA Withdrawal - GuruFocus

Biohaven (BHVN) Faces Market Setback After EMA Withdrawal  GuruFocus

Biohaven (BHVN) Faces Market Setback After EMA Withdrawal - GuruFocus

Click here to get full coverage on Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? - Yahoo Finance

Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In?  Yahoo Finance

Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? - Yahoo Finance

Click here to get full coverage on Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) - PR Newswire

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)  PR Newswire

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) - PR Newswire

Click here to get full coverage on Biohaven (BHVN) Withdraws EMA Application, U.S. Approval Crucial - GuruFocus

Biohaven (BHVN) Withdraws EMA Application, U.S. Approval Crucial  GuruFocus

Biohaven (BHVN) Withdraws EMA Application, U.S. Approval Crucial - GuruFocus

Click here to get full coverage on Biohaven (BHVN) Withdraws Troriluzole Application in Europe, Foc - GuruFocus

Biohaven (BHVN) Withdraws Troriluzole Application in Europe, Foc  GuruFocus

Biohaven (BHVN) Withdraws Troriluzole Application in Europe, Foc - GuruFocus

Click here to get full coverage on Biohaven (BHVN) Options Move Yields 15% Profit in a Day | BHVN S - GuruFocus

Biohaven (BHVN) Options Move Yields 15% Profit in a Day | BHVN S  GuruFocus

Biohaven (BHVN) Options Move Yields 15% Profit in a Day | BHVN S - GuruFocus

Click here to get full coverage on Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors - PR Newswire

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors  PR Newswire

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors - PR Newswire

Click here to get full coverage on Earnings Flash (BHVN) BIOHAVEN LTD. Posts Q4 Loss $-1.71 Per Share, vs. FactSet Est of $-1.49 - marketscreener.com

Earnings Flash (BHVN) BIOHAVEN LTD. Posts Q4 Loss $-1.71 Per Share, vs. FactSet Est of $-1.49  marketscreener.com

Earnings Flash (BHVN) BIOHAVEN LTD. Posts Q4 Loss $-1.71 Per Share, vs. FactSet Est of $-1.49 - marketscreener.com

Click here to get full coverage on Biohaven: A Complicated Tale (NYSE:BHVN) - Seeking Alpha

Biohaven: A Complicated Tale (NYSE:BHVN)  Seeking Alpha

Biohaven: A Complicated Tale (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on Biohaven's Revenue Path: SCA And Obesity Therapies (NYSE:BHVN) - Seeking Alpha

Biohaven's Revenue Path: SCA And Obesity Therapies (NYSE:BHVN)  Seeking Alpha

Biohaven's Revenue Path: SCA And Obesity Therapies (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on Biohaven Lands Major $600 Million Deal With Oberland Capital - Finimize

Biohaven Lands Major $600 Million Deal With Oberland Capital  Finimize

Biohaven Lands Major $600 Million Deal With Oberland Capital - Finimize

Click here to get full coverage on Biohaven Pharma (BHVN) Reports Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia - StreetInsider

Biohaven Pharma (BHVN) Reports Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia  StreetInsider

Biohaven Pharma (BHVN) Reports Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia - StreetInsider

Click here to get full coverage on Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March - The Motley Fool

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March  The Motley Fool

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March - The Motley Fool

Click here to get full coverage on Why BioHaven Stock Is Soaring Today - MSN

Why BioHaven Stock Is Soaring Today  MSN

Why BioHaven Stock Is Soaring Today - MSN

Click here to get full coverage on Biohaven Announces Record Date for Anticipated Spin-Off - PR Newswire

Biohaven Announces Record Date for Anticipated Spin-Off  PR Newswire

Biohaven Announces Record Date for Anticipated Spin-Off - PR Newswire

Click here to get full coverage on Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround - Yahoo Finance

Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround  Yahoo Finance

Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround - Yahoo Finance

Click here to get full coverage on Biohaven Stock: Promising Pipeline Leading The Charge (NYSE:BHVN) - Seeking Alpha

Biohaven Stock: Promising Pipeline Leading The Charge (NYSE:BHVN)  Seeking Alpha

Biohaven Stock: Promising Pipeline Leading The Charge (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day - PR Newswire

Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day  PR Newswire

Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day - PR Newswire

Click here to get full coverage on Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy - PR Newswire

Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy  PR Newswire

Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy - PR Newswire

Click here to get full coverage on Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies - PR Newswire

Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies  PR Newswire

Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies - PR Newswire

Click here to get full coverage on Bengaluru’s iconic Vidyarthi Bhavan now lets you reserve your spot and skip the wait - Hindustan Times

Bengaluru’s iconic Vidyarthi Bhavan now lets you reserve your spot and skip the wait  Hindustan Times

Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Price Chart

Key Statistics

Technicals

About BHVN

Latest News

Biohaven Announces Investment up to $600 Million by Oberland Capital - PR Newswire

Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Yahoo Finance

$BHVN stock is up 7% today. Here's what we see in our data. - Nasdaq

Advanced Charts

Top Gainers

Top Losers